AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05657613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib
Description: Days 1-7: Oral doses of pacritinib 200 mg BID~Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of bosentan 125 mg BID
Study NCT05657613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
Description: Days 1-7: Oral doses of pacritinib 200 mg BID~Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of fluconazole 200 mg QD.
Study NCT05204472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Burst DBS
Description: Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of of Burst-stimulation followed by 12 days active tonic stimulation (Burst-DBS -> tonic-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period).
Study NCT05204472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Burst DBS
Description: Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of of Burst-stimulation followed by 12 days active tonic stimulation (Burst-DBS -> tonic-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period).
Study NCT05204472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tonic DBS
Description: Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of active tonic stimulation followed by 12 days of Burst-stimulation (tonic-DBS -> Burst-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period).
Study NCT05204472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tonic DBS
Description: Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of active tonic stimulation followed by 12 days of Burst-stimulation (tonic-DBS -> Burst-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period).
Study NCT05683886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KC1036
Description: Patients take 60mg QD of KC1036 for the efficacy and safety study. KC1036 are given orally once daily, 21 days as a cycle.
Study NCT04721132 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT04721132 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT04721132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04373356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin Infiltration
Description: Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with a rubber dam and ICON will be applied following the manufacturer's instructions. After that, the rubber dam will be removed and 5% NaF Varnish will be applied.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison.
Study NCT04373356 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride Varnish
Description: Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with cotton roll and 5% NaF varnish will be applied following the manufacturer's instructions.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison.
Study NCT06647316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: The subjects will receive the first physiotherapy session : early mobilization, postural and joint ergonomics, sensory stimulation, temporal-spatial orientation and health education for the patient and the main caregiver are carried out.The plan will progress with postural control in a seated position, head and trunk control, re-education of transfers, balance, standing and walking, depending on the subject's abilities.The second physical therapy session incorporates taste and preference-based elements into the therapy itself. The third physiotherapy session is planned to take place in the physiotherapy unit. Following the individualized session, group interaction is encouraged, whether with other patients, the rehabilitation team and/or the patient's primary caregiver.In the fourth physiotherapy session, it is promoted therapeutic compliance.
Study NCT06646913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Patients will utilize the TENS device for 45 minutes, two times per day for the 4 week treatment period.
Study NCT06646497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation Stem cell source only Bone Marrow
Description: 1. Conditioning regimen Thymoglobulin (0.5/mg/kg à D-9, 2 mg /kg at D-8 and 2.5 mg/kg à D-7), Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant, Cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day -1).~2. Stem cell source Bone Marrow only. Target of 4 × 10\^8 nucleated cells/kg recipient body weight. Granulocyte colony stimulating factor is given subcutaneously starting on day +5 at 5 mg/ kg/day until the absolute neutrophil count is greater than 1.5 × 10\^9/L for 3 days.~3. GVHD prophylaxis Cyclophosphamide 50 mg/Kg/day at D+3 and D+4. Tacrolimus (0,2 à 0,3 mg/kg/day per os divided into 2 doses or 0.05 to 0.1 mg/kg/d IVSE) and mycophenolate (MMF) will begin from D+5. In absence of GvHD, MMF will be stopped between D35 and D45 and Tacrolimus at day 365.~4. Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT (except patients and their donor with EBV serology and EBV PCR negative).
Study NCT06585748 — intervention group
Intervention type: DRUG
Intervention: Lidocaine spray
Description: 4 puffs of lidocaine spray was applied to the glans penis and urethral meatus, and after 5 minutes, the appropriate method and sterilization were used to apply a catheter gel, and a Foley catheter was placed in the bladder. After bladder catheterization, pain scores were evaluated by a neutral emergency medicine physician at 0 minutes (during the procedure), and at 15, 30, and 60 minutes post-procedure. The Face Legs Arms Cry Consolability Pain Scale (FLACC) and Wong-Baker pain scales were used for this evaluation.
Study NCT06585748 — intervention group
Intervention type: OTHER
Intervention: Placebo
Description: No medication/application will be administered as placebo.
Study NCT05708677 — intervention group
Intervention type: BIOLOGICAL
Intervention: EB-101
Description: This is non-interventional and follows patients treated with EB-101
Study NCT04727034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam tosylate
Description: Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.
Study NCT04727034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but propofol significantly inhibits the respiratory and circulatory systems. Therefore, the incidence of intraoperative hypoxemia and hypotension is high.
Study NCT05240664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Have A Say Programme
Description: Each dyad of participants will receive a 4-session ACP programme, which consists of 2 group-based sessions and 2 dyadic sessions, one hour for each session. The group-based sessions are led by nurse which include didactic educational components, guided reflection, videos, and group sharing. Dyads of participants will be provided with information about ACP, the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. The dyadic sessions are facilitated by trained ACP facilitators and guided by an ACP booklet. Dyads of participants will be supported to have an individualized ACP discussion guided by an ACP booklet. By the end of the programme, each dyad of participants will be given an ACP booklet documenting the ACP process.
Study NCT05240664 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention-control health talks
Description: Dyads of participants in the control group will receive 4-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health, and healthy diet.
Study NCT05358964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: African American Family Health History Education Program
Description: The AAFHHEP arm is an intervention to increase utilization of FHH and increase preventative screening. This tool will be culturally tailored by African Americans for African Americans.
Study NCT05358964 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: African American Family Health History Education Program
Description: The AAFHHEP arm is an intervention to increase utilization of FHH and increase preventative screening. This tool will be culturally tailored by African Americans for African Americans.
Study NCT04685317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentinel® Cerebral Protection System
Description: A percutaneously delivered dual-filter protection device, designed to capture and remove debris dislodged during transcatheter aortic valve replacement procedures.
Study NCT04685317 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
Study NCT04685317 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
Study NCT05540262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone
Description: Edaravone injection 30mg three times a day
Study NCT05613504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture treatment
Description: Acupoint selection: 4 general points + syndrome differentiation acupoints (select or replace 2-4 acupoints according to symptom 1, select 1-2 acupoints according to symptom 2 and symptom 3), and adjust acupoints according to symptoms every week.~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: Use a one-time sterile acupuncture needle (0.30×40mm, Huatuo brand), insert the needle 0.5 inch along the anatomical position, level up and relieve the qi, and keep the needle for 20 minutes.
Study NCT05613504 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture treatment
Description: Acupoint selection: According to the selected acupoints of the electroacupuncture group, 5-7 positions were selected at the non-meridian and non-acupoint points(points with less nerve distribution, sparseness, and rich muscles).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: ① Shallow needling scheme: use a disposable sterile acupuncture needle, insert the needle 0.2 inch, without twisting, and keep the needle for 20 minutes. ②Non-invasive acupuncture plan: choose a special comfort needle with no needle tip at the top of the needle, paste a disposable sterile foam pad on the non-acupoint, and use a disposable sterile flat head The acupuncture needles were pierced into the foam pad, lightly touching but not piercing the skin, and not breathing; the needles were kept for 20 minutes.
Study NCT04769895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MaaT013
Description: MaaT013 is made of allogeneic, full-ecosystem pooled biotherapeutic intestinal microbiota
Study NCT06401096 — intervention group
Intervention type: PROCEDURE
Intervention: Preoperative respiratory exercises
Description: The Triflo Exerciser
Study NCT04605393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: CBD
Study NCT04605393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04605393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-THC
Description: THC
Study NCT04764084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 100mg or 200mg, PO, qd，d1-d21
Study NCT04764084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12mg, PO, qd，d1-d14
Study NCT00698074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronisation Therapy
Description: Biventricular Pacemaker Implant
Study NCT05810506 — intervention group
Intervention type: OTHER
Intervention: In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.
Description: In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.
Study NCT04890977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talking Story
Description: A culturally grounded modular intervention to increase mental health treatment-seeking among Pacific Islanders.
Study NCT04890977 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Talking Story
Description: A culturally grounded modular intervention to increase mental health treatment-seeking among Pacific Islanders.
Study NCT05383092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Physical Activity Strong
Description: Children will practice physical activities combining aerobics and muscle strengthening. They will follow a 30-minute (for prepubescent children) or 60-minute (for pubescent children) Strong adapted physical activity session 2 to 3 times a week during hospitalization periods or by videoconference at home when they are not hospitalized.
Study NCT05383092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity Strong
Description: Children will practice physical activities combining aerobics and muscle strengthening. They will follow a 30-minute (for prepubescent children) or 60-minute (for pubescent children) Strong adapted physical activity session 2 to 3 times a week during hospitalization periods or by videoconference at home when they are not hospitalized.
Study NCT04566133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: orally 2 mg once a day
Study NCT04566133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: orally 600 mg twice a day-1,200 mg total dose
Study NCT04889521 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention. Study is cross-sectional observational.
Study NCT06606574 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Titration protocol
Description: A standardized titration protocol for ITB will be used and the ITB dose will be increased to the next step if 1) there is persistent hypertonia identified on the dystonia screener or ASAS total spasticity, or 2) there is room for improvement on the D-FIS, and 3) there are no detrimental side effects (e.g., worsening head control). This will be continued until 1) dystonia and spasticity have been eliminated or no longer deemed as functionally impairing by the medical team, 2) side effects prevent further titration, or 3) a maximum dose of 2000 mcg/day has been reached. Once steady state is reached, this new dose becomes the maintenance dose for the rest of the trial. If there are detrimental side effects, the child will be seen weekly to confirm resolution of side effects. If side effects persist, the child will be reduced at each visit to the previous step. Once side effects are controlled, this new dose becomes the child's maintenance dose for the rest of the trial.
Study NCT06614296 — intervention group
Intervention type: PROCEDURE
Intervention: Crenel Lateral Interbody Fusion
Description: The Crenel Lateral Interbody Fusion (CLIF) is a surgical technique developed by the Department of Spine Surgery at the Second Affiliated Hospital of Zhejiang University School of Medicine. Building on the traditional Lateral Lumbar Interbody Fusion technique, this series of technical improvements overcomes the shortcomings of previous surgical methods, enhancing the safety, operability, and effectiveness of the surgery while reducing complications.
Study NCT06614296 — intervention group
Intervention type: PROCEDURE
Intervention: Crenel lateral interbody fusion plus second stage surgery
Description: The patient was first admitted to undergo CLIF surgery and was discharged after the operation. The patient will return to the hospital for a second surgery at the scheduled time.
Study NCT06617884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait and balance training
Description: The training includes individually adapted, targeted, video-based coordination and balance training, which should lead to an improvement in gait and balance. It includes strength, coordination and flexibility exercises.
Study NCT06621225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence
Description: Medtronic GI Genius is an advanced AI-powered platform designed to assist gastroenterologists during colonoscopies. Utilizing deep learning algorithms, it analyzes real-time endoscopic images to detect and highlight polyps and other abnormalities, enhancing the detection rate and accuracy. The system provides visual cues to guide physicians in identifying potentially problematic areas that might be missed by the human eye alone. This technology aims to improve diagnostic precision, reduce missed detections, and ultimately enhance patient outcomes by facilitating earlier and more accurate interventions. GI Genius integrates seamlessly with existing endoscopy equipment, offering a valuable tool in the fight against colorectal cancer.
Study NCT06621225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucosal Exposure Device
Description: The Olympus Endocuff is an innovative device designed to enhance the effectiveness of colonoscopy procedures. It is a soft, flexible cuff that attaches to the end of the colonoscope and features multiple protruding \&#34;fingers\&#34; that help to improve mucosal exposure. By providing better visibility and maneuverability, the Endocuff helps gastroenterologists navigate and inspect the colon more thoroughly. It aids in the detection of polyps and other abnormalities by flattening folds and improving the overall view of the colon lining. This enhanced visualization contributes to more accurate diagnoses and can potentially reduce the miss rate of significant lesions, ultimately leading to better patient outcomes.
Study NCT06622018 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Seashell Nanoparticles and Gluma Desensitizer
Description: Evaluation the effect of Seashell Nano Particles and Gluma desensitizer on sensitivity of the teeth for Intra coronal restoration at different times
Study NCT06622018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seashell Nanoparticles and Gluma Desensitizer
Description: Evaluation the effect of Seashell Nano Particles and Gluma desensitizer on sensitivity of the teeth for Intra coronal restoration at different times